Finance

Lists
601607:SHA
Shanghai Pharmaceuticals Holding Ord Shs A
16,61 CN¥
-0,89%
(-0,15) 1D
16-окт., 15:00:02 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 601607...
Open
16,71 CN¥
High
16,91 CN¥
Low
16,52 CN¥
Mkt. cap
55,57 млд
Avg. vol.
9,85 млн
Volume
14,44 млн
Dividend
2,71%
Quarterly dividend
0,11 CN¥
Ex-dividend date
2026-ж., 18-сен.
P/E ratio
12,90
52-wk high
18,56 CN¥
52-wk low
15,01 CN¥
EPS
1,29 CN¥
Shares outstanding
1,92 млд
No. of employees
49 миң
Open
16,71 CN¥
High
16,91 CN¥
Low
16,52 CN¥
Mkt. cap
55,57 млд
Avg. vol.
9,85 млн
Volume
14,44 млн
Dividend
2,71%
Quarterly dividend
0,11 CN¥
Ex-dividend date
2026-ж., 18-сен.
P/E ratio
12,90
52-wk high
18,56 CN¥
52-wk low
15,01 CN¥
EPS
1,29 CN¥
Shares outstanding
1,92 млд
No. of employees
49 миң
News stories
From web sources and news partners
Profile
Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia
About Shanghai Pharmaceuticals Holding Ord Shs A
CEO-
Employees48,6 миң
Founded1994-ж., 18-янв.
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
73,48 млд
68,51 млд
75,26 млд
72,21 млд
Cost of goods sold
66,03 млд
60,55 млд
67,17 млд
64,09 млд
Cost of revenue
66,03 млд
60,55 млд
67,17 млд
64,09 млд
Research and development expenses
556,53 млн
824,53 млн
468,22 млн
502,64 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,70 млд
4,97 млд
4,59 млд
4,65 млд
Operating expense
5,58 млд
5,91 млд
5,47 млд
5,55 млд
Total operating expenses
71,60 млд
66,47 млд
72,63 млд
69,64 млд
Operating income
1,88 млд
2,04 млд
2,63 млд
2,57 млд
Other non operating income
-84,84 млн
-63,65 млн
-47,88 млн
-7,43 млн
EBT including unusual items
1,48 млд
1,52 млд
2,42 млд
3,21 млд
EBT excluding unusual items
1,61 млд
1,44 млд
2,27 млд
3,03 млд
Income tax expense
485,91 млн
534,14 млн
569,09 млн
720,64 млн
Effective tax rate
32,89%
35,10%
23,52%
22,43%
Other operating expenses
129,62 млн
271,29 млн
132,16 млн
186,62 млн
Net income
688,20 млн
577,49 млн
1,42 млд
2,09 млд
Net profit margin
0,94%
0,84%
1,88%
2,89%
Earnings per share
-
-
-
-
Interest and investment income
206,57 млн
-
38,70 млн
873,52 млн
Interest expense
-393,02 млн
-470,36 млн
-347,64 млн
-358,39 млн
Net interest expenses
-186,45 млн
-470,36 млн
-308,94 млн
515,13 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
2,26 млд
2,54 млд
3,12 млд
3,07 млд
Gain or loss from assets sale
39,99 млн
-157,15 млн
-
-179,70 млн
AI content may include mistakes. Learn more
Google колдонмолору